Nuveen Asset Management, LLC Apellis Pharmaceuticals, Inc. Transaction History

Nuveen Asset Management, LLC

$334 Billion
Q2 2024

A detailed history of Nuveen Asset Management, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 280,001 shares of APLS stock, worth $7.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

280,001

Previous 270,576 3.48%

Holding current value

$7.77 Million

Previous $15.9 Million 32.47%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$38.07 - $59.71 $358,809 - $562,766	9,425 Added 3.48%	280,001 $10.7 Million
Q1 2024 May 13, 2024	BUY	$55.39 - $72.47 $3,101 - $4,058	56 Added 0.02%	270,576 $15.9 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $111,160 - $194,006	-2,993 Reduced 1.09%	270,520 $16.2 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $262,869 - $991,680	11,115 Added 4.24%	273,513 $10.4 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $6.68 Million - $8.13 Million	-87,156 Reduced 24.93%	262,398 $23.9 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $520,922 - $748,679	-11,181 Reduced 3.1%	349,554 $23.1 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $2.15 Million - $3.03 Million	-49,666 Reduced 12.1%	360,735 $18.7 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $1.53 Million - $2.38 Million	34,201 Added 9.09%	410,401 $28 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $3.95 Million - $6.66 Million	112,555 Added 42.69%	376,200 $17 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $255,453 - $389,880	7,204 Added 2.81%	263,645 $13.7 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $301,344 - $481,915	-9,803 Reduced 3.68%	256,441 $10.8 Million
Q3 2021 Nov 12, 2021	SELL	$31.4 - $69.84 $2.04 Million - $4.54 Million	-64,935 Reduced 19.61%	266,244 $9.11 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $2.75 Million - $4.36 Million	67,218 Added 25.47%	331,179 $20.9 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $181,764 - $255,672	-4,455 Reduced 1.66%	263,961 $11.3 Million
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $127,193 - $236,293	-4,131 Reduced 1.52%	268,416 $15.4 Million
Q3 2020 Nov 16, 2020	BUY	$25.89 - $33.65 $5,488 - $7,133	212 Added 0.08%	272,547 $8.22 Million
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $2.19 Million - $3.41 Million	-88,470 Reduced 24.52%	272,335 $8.89 Million
Q1 2020 May 14, 2020	BUY	$17.91 - $44.33 $2.98 Million - $7.37 Million	166,194 Added 85.4%	360,805 $9.67 Million
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $442 - $616	-20 Reduced 0.01%	194,611 $5.96 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $542,097 - $724,146	22,503 Added 13.07%	194,631 $4.69 Million
Q2 2019 Aug 15, 2019	BUY	$18.0 - $25.34 $3.1 Million - $4.36 Million	172,128 New	172,128 $4.36 Million

Others Institutions Holding APLS

# of Institutions

299

Shares Held

113M

Call Options Held

5.21M

Put Options Held

691K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.05B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Apellis Pharmaceuticals, Inc. Transaction History